FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis

Table 3 Clinical characteristics of 279 patients with metabolic dysfunction-associated steatotic liver disease

Project	Overall population (n = 279)	High-risk MASH group (n = 93)	Non-high-risk MASH group (n = 186)	P value
Demographics
Male	126 (45.2)	28 (30.1)	98 (52.7)	< 0.05
Age (yr)	41.0 (30.0, 53.0)	48.0 (36.5, 57.0)	38.0 (29.0, 50.0)	< 0.05
BMI (kg/m2)	26.8 ± 3.4	27.3 ± 3.2	26.5 ± 3.6	0.26
Metabolic disease
Dysglycemia	187 (67.0)	72 (77.4)	115 (61.8)	< 0.05
Hypertension	72 (25.8)	32 (34.4)	40 (21.5)	< 0.05
Hyperlipidemia	37 (13.3)	18 (19.4)	19 (10.2)	< 0.05
Hypertriglyceridemia	150 (53.8)	44 (47.3)	106 (57.0)	0.13
Low HDL-C	202 (72.4)	73 (78.5)	129 (69.4)	0.11
Serologic indicators
TC (mmol/L)	4.9 ± 1.0	4.9 ± 1.0	4.9 ± 1.0	0.51
TG (mmol/L)	1.8 (1.3, 2.7)	1.7 (1.1, 2.3)	1.9 (1.3, 2.8)	0.08
HDL-C (mmol/L)	1.0 (0.9, 1.2)	1.1 (0.9, 1.2)	1.0 (0.9, 1.2)	0.70
LDL-C (mmol/L)	3.0 ± 0.8	2.9 ± 0.9	3.0 ± 0.8	0.75
Fasting blood glucose (mmol/L)	5.9 (5.4, 6.7)	6.3 (5.6, 7.2)	5.7 (5.3, 6.4)	< 0.05
PLT (× 109/L)	222.8 ± 66.1	205.6 ± 68.4	231.4 ± 63.3	< 0.05
ALT (U/L)	90.6 (55.7, 145.5)	99.1 (55.9, 148.8)	86.0 (55.2, 139.0)	0.28
AST (U/L)	50.1 (31.4, 81.2)	65.0 (37.7, 107.5)	43.8 (29.9, 62.4)	< 0.05
ALP (U/L)	82.0 (65.8, 98.5)	83.1 (69.5, 98.9)	79.9 (64.7, 98.4)	0.36
GGT (U/L)	63.5 (38.8, 103.1)	71.5 (45.7, 103.0)	60.4 (35.9, 105.6)	0.09
TBIL (μmol/L)	12.3 (9.4, 16.5)	13.0 (10.0, 17.5)	11.7 (9.1, 15.9)	0.08
ALB (g/L)	46.1 (43.0, 48.9)	44.8 (42.1, 48.0)	46.7 (43.7, 49.4)	< 0.05
HGB (g/L)	144.0 (134.0, 156.0)	141.3 (132.0, 153.0)	146.0 (134.9, 158.0)	0.07
Apolipoprotein A1 (g/L)	1.3 (1.2, 1.5)	1.4 (1.2, 1.5)	1.3 (1.2, 1.5)	< 0.05
Apolipoprotein B (g/L)	1.0 (0.8, 1.1)	0.9 (0.7, 1.2)	1.0 (0.8, 1.1)	0.95
Cr (μmol/L)	61.5 (52.4, 73.0)	56.9 (50.9, 67.3)	63.0 (53.0, 74.1)	< 0.05
Urea (mmol/L)	4.5 (3.8, 5.4)	4.5 (3.7, 5.4)	4.5 (3.8, 5.2)	0.97
Uric acid (μmol/L)	367.0 (301.0, 433.0)	369.0 (282.8, 443.0)	363.5 (304.0, 425.9)	0.67
eGFR (mL/min)	110.6 (100.6, 120.2)	108.0 (98.5, 114.9)	114.0 (105.0, 124.0)	< 0.05
PT (s)	11.3 (10.7, 11.9)	11.6 (11.1, 12.3)	11.2 (10.6, 11.7)	< 0.05
Non-invasive models
FIB-4	0.9 (0.6, 1.6)	1.4 (1.0, 2.8)	0.8 (0.6, 1.2)	< 0.05
APRI	0.6 (0.4, 1.0)	0.9 (0.5, 1.5)	0.5 (0.3, 0.8)	< 0.05
Forns index	4.2 (3.0, 5.6)	5.0 (3.7, 6.3)	3.9 (2.7, 4.9)	< 0.05
ARR	0.6 (0.5, 0.7)	0.6 (0.5, 0.9)	0.5 (0.4, 0.7)	< 0.05
S index	0.1 (0.1, 0.3)	0.2 (0.1, 0.3)	0.1 (0.1, 0.2)	< 0.05
GPR	0.7 (0.4, 1.2)	0.8 (0.5, 1.3)	0.6 (0.3, 1.0)	< 0.05

All data are presented as n (%) or mean ± SD or M (P25, P75). MASH: Metabolic dysfunction-associated steatohepatitis; BMI: Body mass index; HDL-C: High density lipoprotein cholesterol; TC: Total cholesterol; TG: Triglycerides; LDL-C: Low density lipoprotein cholesterol; PLT: Platelets; ALT: Alanine transaminase; AST: Aspartate transaminase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; TBIL: Total bilirubin; ALB: Albumin; HGB: Hemoglobin; Cr: Creatinine; eGFR: Estimated glomerular filtration rate; PT: Prothrombin time; FIB-4: Fibrosis-4; APRI: Aspartate transaminase to platelet ratio index; ARR: Aspartate transaminase to alanine transaminase ratio; GPR: Gamma-glutamyl transpeptidase to platelet ratio.